DRI Biosciences Corporation is developing proprietary and game-changing therapeutics to improve conditions of Fragile X Syndrome (FXS) and Autism Spectrum Disorder (ASD). FXS represents the most common form of inherited intellectual disability and is a frequent monogenic cause of autism. In the U.S. and Europe, there are more than 100,000 cases of FXS. Meanwhile, the total autistic incidence is approaching 2 million worldwide. The predicted therapeutic market is estimated at $5.5 billion by 2018, but there are no medications that effectively treat or improve these neurodevelopmental conditions.
Company Details
- Address
- 4985 Winchester Blvd, Frederick,maryland 21703,united States
- Industry
- Biotechnology
- Website
- https://www.dribiosciences.com
- Keywords
- Pikesville.
- HQ
- FREDERICK, Maryland
Dri Biosciences Corp Questions
Dri Biosciences Corp's website is https://www.dribiosciences.com
Dri Biosciences Corp's LinkedIn profile is https://www.linkedin.com/company/dri-biosciences-corp
Dri Biosciences Corp's industry is
Biotechnology
Dri Biosciences Corp's top competitors are
Providion Us,
Pathotrak,
Benekinetic, Inc.,
Hartedge Bioops Consulting Llc,
Brayearst Validation Consulting,
Forge Forward Engineering,
Engineex Llc,
Wearabledose,
Pulpfixin,
Phylloceuticals.
Dri Biosciences Corp's categories are Biotechnology
